Navigation Links
Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant
Date:7/20/2011

CLEVELAND, July 20, 2011 /PRNewswire/ -- One of Frantz Medical Group's (FMG) subsidiaries, VasoStar Inc., Mentor, Ohio  today announced that it has been awarded an Ohio Third Frontier grant to further develop and commercialize a novel electromagnetic guidewire system for penetrating through vascular Chronic Total Occlusions (CTOs), in lieu of invasive open heart surgery such as Coronary Artery Bypass Graft (CABG).  

VasoStar's primary clinical development partner is the Cleveland Clinic's Lerner Research Institute.  The VasoStar advisory team consists of world renowned cardiovascular clinicians including Dr. Patrick Whitlow, Director of Interventional Cardiology, Cleveland Clinic; Dr. Kiyo Fukamachi, Director of the Cardiovascular Dynamics Laboratory, Lerner Research Institute, Cleveland Clinic; Dr. Marc Penn, Director of Research, Summa Cardiovascular Institute; and Dr. Peter Fitzgerald, Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL),  Stanford University Medical School. VasoStar has also received grant support and technical and commercial counsel from the Global Cardiovascular Innovation Center (GCIC), an Ohio based product commercialization consortium led by the Cleveland Clinic.

This $1,000,000 grant, in addition to FMG's financial and engineering support, will allow VasoStar to complete development of and collect additional safety data for the guidewire and catheter system in preparation for FDA and CE regulatory submissions.  The VasoStar technology has been demonstrated to be safe in an animal study performed at the Lerner Research Institute.  A number of preeminent interventional cardiologists have provided positive feedback regarding the VasoStar system's usability and potential effectiveness following hands-on experience with prototype devices in arterial pathway models with simulated blockages.  With the assistance of the Ohio Third Frontier grant, VasoStar will develop the first guidewire system that offers the clinician on-demand CTO-crossing assistance from the guidewire's embedded miniaturized electromagnetic engines.  Product launch is targeted for 2013.

"We are delighted and grateful to have the support of the State of Ohio," said Stephanie Harrington, Chief Operating Officer of VasoStar.  "The Ohio Third Frontier grant will allow us to further the development of an effective solution to crossing CTOs with a guidewire which will improve patient outcome without altering the clinician's guidewire technique. In addition, this grant offers VasoStar the ability to build and expand Northeast Ohio's cardiovascular medical device engineering and manufacturing competency in partnership with the Cleveland Clinic and Interplex Medical."

About VasoStar Inc.

VasoStar Inc. was established to develop and commercialize a solution to the unmet need for a CTO crossing percutaneously: a miniaturized electromagnetic solenoid that produces longitudinal vibration at the guidewire tip for safely penetrating CTOs without significantly changing the clinician's guidewire technique and feel. VasoStar has exclusively licensed this technology from EYoCa Medical Ltd., an Israeli company founded by three Israeli scientists, including VasoStar's Chief Technology Officer, Mr. Ran Carmeli, and two leading U.S. interventional cardiovascular clinicians and researchers, the late Dr. Donald Baim, Chief Scientific and Medical Officer, Boston Scientific (previously Professor, Harvard Medical School) and Professor Peter Fitzgerald, Stanford University School of Medicine. Frantz Medical Group (www.FrantzGroup.com), established in 1979, is an Ohio-based consortium of companies specializing in the development and manufacturing of medical devices and diagnostics. FMG has majority ownership of VasoStar Inc. and has incubated VasoStar's initial development efforts.

About Ohio Third Frontier

The Ohio Third Frontier targets its investments to support technology areas that represent Ohio's key competitive opportunities. The Ohio Third Frontier was created in 2002 and is an unprecedented commitment to create new technology-based products, companies, industries and jobs. Their programs accelerate the growth and development of the biomedical, medical imaging, and sensors industries and their supply chains in Ohio.


'/>"/>
SOURCE Frantz Medical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
2. Frantz Medical Group Announces the Promotion of Stephanie Harrington to Chief Operating Officer
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Globus Medical Raises $110 Million in Series E Financing Round
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Boston University Biomedical Engineers Find Chink in Bacterias Armor
9. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
10. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):